factual
Conflicted Votes Kept COX-2 Drugs on Market
At the 2005 FDA advisory hearings on COX-2 inhibitors, 10 of the 32 committee members had financial ties to Merck or Pfizer, and had those conflicted votes been discounted, all the drugs except a black-box-warned Celebrex would have been removed from the market.
factualpending
Speaker
Marcia AngellEvidence Quote
“Ten of the 32 had financial conflicts of interest. And if those votes had been discounted, all of those drugs would be taken off the market except for Celebrex”
Created: 6/13/2026, 12:08:22 AM
Your notes
Loading notes...